Korro Bio (NASDAQ:KRRO) Director Jean Francois Formela Sells 2,143 Shares

Posted by Brenda Bartman on Aug 14th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Francois Formela sold 2,143 shares of Korro Bio stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $13.96, for a total value of $29,916.28. Following the completion of the transaction, the director owned 145,937 shares of the company’s stock, valued at approximately $2,037,280.52. This represents a 1.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Francois Formela also recently made the following trade(s):

On Monday, July 6th, Jean Francois Formela sold 9,323 shares of Korro Bio stock. The shares were sold at an average price of $13.96, for a total value of $130,149.08.
On Thursday, July 2nd, Jean Francois Formela sold 100,700 shares of Korro Bio stock. The shares were sold at an average price of $14.03, for a total value of $1,412,821.00.
On Wednesday, June 24th, Jean Francois Formela sold 48,438 shares of Korro Bio stock. The shares were sold at an average price of $14.61, for a total value of $707,679.18.
On Tuesday, June 23rd, Jean Francois Formela sold 119,005 shares of Korro Bio stock. The stock was sold at an average price of $14.25, for a total value of $1,695,821.25.
On Monday, June 22nd, Jean Francois Formela sold 3,962 shares of Korro Bio stock. The shares were sold at an average price of $13.95, for a total value of $55,269.90.
On Thursday, May 28th, Jean Francois Formela sold 2,860 shares of Korro Bio stock. The shares were sold at an average price of $13.95, for a total value of $39,897.00.

Korro Bio Stock Down 0.4%

Shares of KRRO opened at $13.29 on Friday. The business has a fifty day moving average of $12.34 and a 200 day moving average of $12.18. The company has a market cap of $195.76 million, a PE ratio of -1.33 and a beta of 3.04. Korro Bio, Inc. has a 52-week low of $5.20 and a 52-week high of $55.89.

Korro Bio (NASDAQ:KRRO – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.27. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $0.21 million. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 114.26%. As a group, research analysts anticipate that Korro Bio, Inc. will post -4.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on KRRO shares. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright dropped their target price on Korro Bio from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Monday, July 6th. Lifesci Capital upgraded Korro Bio to a “strong-buy” rating in a report on Friday, May 29th. Finally, Citigroup assumed coverage on Korro Bio in a report on Monday, May 18th. They issued a “buy” rating and a $21.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.71.

Read Our Latest Analysis on KRRO

Institutional Trading of Korro Bio

Large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Korro Bio in the second quarter worth about $10,776,000. Affinity Asset Advisors LLC bought a new stake in Korro Bio during the 1st quarter valued at about $8,002,000. Nantahala Capital Management LLC bought a new stake in Korro Bio during the 4th quarter valued at about $4,806,000. ADAR1 Capital Management LLC purchased a new stake in Korro Bio in the 1st quarter valued at about $6,113,000. Finally, TCG Crossover Management LLC purchased a new stake in Korro Bio in the 3rd quarter valued at about $19,937,000. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.